|
1.
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2.
|
DeSantis C, Siegel R, Bandi P and Jemal A:
Breast cancer statistics, 2011. CA Cancer J Clin. 61:409–418. 2011.
View Article : Google Scholar
|
|
3.
|
Siegel R, Ward E, Brawley O and Jemal A:
Cancer statistics, 2011: the impact of eliminating socioeconomic
and racial disparities on premature cancer deaths. CA Cancer J
Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Curtis RE, Freedman DM, Ron E, Ries LAG,
Hacker DG, Edwards BK, Tucker MA and Fraumeni JF Jr: New
malignancies following breast cancer. New Malignancies Among Cancer
Survivors: SEER Cancer Registries, 1973–2000. National Cancer
Institute, NIH Publishing; Bethesda, MD: pp. 181–205. 2006
|
|
5.
|
Eifel P, Axelson J, Costa J, et al:
National Institutes of Health Consensus Development Conference
Statement: adjuvant therapy for breast cancer, November 1–3, 2000.
J Natl Cancer Inst. 93:979–989. 2001.
|
|
6.
|
Carlson RW, Allred DC, Anderson BO, et al:
Invasive breast cancer. J Natl Compr Canc Netw. 9:136–222.
2011.
|
|
7.
|
Tallman M, Gray R, Bennett J, et al:
Leukemogenic potential of adjuvant chemotherapy for early-stage
breast cancer: the Eastern Cooperative Oncology Group experience. J
Clin Oncol. 13:1557–1563. 1995.PubMed/NCBI
|
|
8.
|
Campone M, Roche H, Kerbrat P, et al:
Secondary leukemia after epirubicin-based adjuvant chemotherapy in
operable breast cancer patients: 16 years experience of the French
Adjuvant Study Group. Ann Oncol. 16:1343–1351. 2005.
|
|
9.
|
Renella R, Verkooijen HM, Fioretta G, et
al: Increased risk of acute myeloid leukaemia after treatment for
breast cancer. Breast. 15:614–619. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Bernard-Marty C, Mano M, Paesmans M, et
al: Second malignancies following adjuvant chemotherapy: 6-year
results from a Belgian randomized study comparing cyclophosphamide,
methotrexate and 5-fluorouracil (CMF) with an anthracycline-based
regimen in adjuvant treatment of node-positive breast cancer
patients. Ann Oncol. 14:693–698. 2003.
|
|
11.
|
Bonadonna G, Brusamolino E, Valagussa P,
et al: Combination chemotherapy as an adjuvant treatment in
operable breast cancer. N Engl J Med. 294:405–410. 1976. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Martin M, Villar A, Sole-Calvo A, et al
GEICAM Group (Spanish Breast Cancer Research Group): Doxorubicin in
combination with fluorouracil and cyclophosphamide (i.v. FAC
regimen, day 1, 21) versus methotrexate in combination with
fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as
adjuvant chemotherapy for operable breast cancer: a study by the
GEICAM group. Ann Oncol. 14:833–842. 2003.PubMed/NCBI
|
|
13.
|
Fumoleau P, Kerbrat P, Romestaing P, et
al: Randomized trial comparing six versus three cycles of
epirubicin-based adjuvant chemotherapy in premenopausal,
node-positive breast cancer patients: 10-year follow-up results of
the French Adjuvant Study Group 01 trial. J Clin Oncol. 21:298–305.
2003.
|
|
14.
|
Benson JR, Jatoi I, Keisch M, Esteva FJ,
Makris A and Jordan VC: Early breast cancer. Lancet. 373:1463–1479.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
No authors listed. Tamoxifen for early
breast cancer: an overview of the randomised trials. Early Breast
Cancer Trialists’ Collaborative Group. Lancet. 351:1451–1467.
1998.
|
|
16.
|
Fisher B, Jeong JH, Bryant J, et al:
Treatment of lymph-node-negative, oestrogen-receptor-positive
breast cancer: long-term findings from National Surgical Adjuvant
Breast and Bowel Project randomized clinical trials. Lancet.
364:858–868. 2004. View Article : Google Scholar
|
|
17.
|
Burstein HJ, Prestrud AA, Seidenfeld J, et
al: American Society of Clinical Oncology clinical practice
guideline: update on adjuvant endocrine therapy for women with
hormone receptor-positive breast cancer. J Clin Oncol.
28:3784–3796. 2010. View Article : Google Scholar
|
|
18.
|
Slamon DJ, Leyland-Jones B, Shak S, et al:
Use of chemotherapy plus a monoclonal antibody against HER2 for
metastatic breast cancer that overexpresses HER2. N Engl J Med.
344:783–792. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Geyer CE, Forster J, Lindquist D, Chan S,
Romieu CG, Pienkowski T, et al: Lapatinib plus capecitabine for
HER2-positive advanced breast cancer. N Engl J Med. 355:2733–2743.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Gradishar WJ: HER2 therapy - an abundance
of riches. N Engl J Med. 366:176–178. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Patt DA, Duan Z, Fang S, Hortobagyi GN and
Giordano SH: Acute myeloid leukemia after adjuvant breast cancer
therapy in older women: understanding risk. J Clin Oncol.
25:3871–3876. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Leone G, Pagano L, Ben-Yehuda D and Voso
MT: Therapy-related leukemia and myelodysplasia: susceptibility and
incidence. Haematologica. 92:1389–1398. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Le Deley MC, Suzan F, Cutuli B, et al:
Anthracyclines, mitoxantrone, radiotherapy, and granulocyte
colony-stimulating factor: risk factors for leukemia and
myelodysplastic syndrome after breast cancer. J Clin Oncol.
25:292–300. 2007.PubMed/NCBI
|
|
24.
|
Curtis RE, Boice JD Jr, Stovall M, et al:
Risk of leukemia after chemotherapy and radiation treatment for
breast cancer. N Engl J Med. 326:1745–1751. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Fisher B, Rockette H, Fisher ER, Wickerham
DL, Redmond C and Brown A: Leukemia in breast cancer patients
following adjuvant chemotherapy or postoperative radiation: the
NSABP experience. J Clin Oncol. 3:1640–1658. 1985.PubMed/NCBI
|
|
26.
|
Valagussa P, Moliterni A, Terenziani M,
Zambetti M and Bonadonna G: Second malignancies following CMF-based
adjuvant chemotherapy in resectable breast cancer. Ann Oncol.
5:803–808. 1994.PubMed/NCBI
|
|
27.
|
Pedersen-Bjergaard J, Pedersen M, Roulston
D and Philip P: Different genetic pathways in leukemogenesis for
patients presenting with therapy-related myelodysplasia and
therapy-related acute myeloid leukemia. Blood. 86:3542–3552.
1995.
|
|
28.
|
Smith RE, Bryant J, DeCillis A and
Anderson S; National Surgical Adjuvant Breast and Bowel Project
Experience: Acute myeloid leukemia and myelodysplastic syndrome
after doxorubicin-cyclophosphamide adjuvant therapy for operable
breast cancer: the National Surgical Adjuvant Breast and Bowel
Project Experience. J Clin Oncol. 21:1195–1204. 2003. View Article : Google Scholar
|
|
29.
|
Praga C, Bergh J, Bliss J, et al: Risk of
acute myeloid leukemia and myelodysplastic syndrome in trials of
adjuvant epirubicin for early breast cancer: correlation with doses
of epirubicin and cyclophosphamide. J Clin Oncol. 23:4179–4191.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Moebus V, Jackisch C, Lueck HJ, et al:
Intense dose-dense sequential chemotherapy with epirubicin,
paclitaxel, and cyclophosphamide compared with conventionally
scheduled chemotherapy in high-risk primary breast cancer: mature
results of an AGO phase III study. J Clin Oncol. 28:2874–2880.
2010. View Article : Google Scholar
|
|
31.
|
Chaplain G, Milan C, Sgro C, Carli PM and
Bonithon-Kopp C: Increased risk of acute leukemia after adjuvant
chemotherapy for breast cancer: a population-based study. J Clin
Oncol. 18:2836–2842. 2000.PubMed/NCBI
|
|
32.
|
Jones S, Holmes FA, O’Shaughnessy J, et
al: Docetaxel with cyclophosphamide is associated with an overall
survival benefit compared with doxorubicin and cyclophosphamide:
7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol.
27:1177–1183. 2009.PubMed/NCBI
|
|
33.
|
Roché H, Fumoleau P, Spielmann M, et al:
Sequential adjuvant epirubicin-based and docetaxel chemotherapy for
node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J
Clin Oncol. 24:5664–5671. 2006.
|
|
34.
|
Burnell M, Levine MN, Chapman JA, Bramwell
V, Gelmon K, Walley B, et al: Cyclophosphamide, epirubicin, and
fluorouracil versus dose-dense epirubicin and cyclophosphamide
followed by paclitaxel versus doxorubicin and cyclophosphamide
followed by paclitaxel in node-positive or high-risk node-negative
breast cancer. J Clin Oncol. 28:77–82. 2010. View Article : Google Scholar
|
|
35.
|
Hershman D, Neugut AI, Jacobson JS, et al:
Acute myeloid leukemia or myelodysplastic syndrome following use of
granulocyte colony-stimulating factors during breast cancer
adjuvant chemotherapy. J Natl Cancer Inst. 99:196–205. 2007.
View Article : Google Scholar
|
|
36.
|
Citron ML, Berry DA, Cirrincione C, et al:
Randomized trial of dose-dense versus conventionally scheduled and
sequential versus concurrent combination chemotherapy as
postoperative adjuvant treatment of node-positive primary breast
cancer: first report of Intergroup Trial C9741/Cancer and Leukemia
Group B Trial 9741. J Clin Oncol. 21:1431–1439. 2003.
|
|
37.
|
Tarella C, Passera R, Magni M, et al: Risk
factors for the development of secondary malignancy after high-dose
chemotherapy and autograft, with or without rituximab: a 20-year
retrospective follow-up study in patients with lymphoma. J Clin
Oncol. 29:814–824. 2011.
|
|
38.
|
Mellemkjaer L, Friis S, Olsen JH, et al:
Risk of second cancer among women with breast cancer. Int J Cancer.
118:2285–2292. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Swerdlow AJ and Jones ME; British
Tamoxifen Second Cancer Study Group: Tamoxifen treatment for breast
cancer and risk of endometrial cancer: a case-control study. J Natl
Cancer Inst. 97:375–384. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Schaapveld M, Visser O, Louwman WJ, et al:
The impact of adjuvant therapy on contralateral breast cancer risk
and the prognostic significance of contralateral breast cancer: a
population based study in the Netherlands. Breast Cancer Res Treat.
110:189–197. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Li CI, Daling JR, Porter PL, Tang MT and
Malone KE: Adjuvant hormonal therapy for breast cancer and risk of
hormone receptor-specific subtypes of contralateral breast cancer.
Cancer Res. 69:6865–6870. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Baum M, Budzar AU, Cuzick J, et al:
Anastrozole alone or in combination with tamoxifen versus tamoxifen
alone for adjuvant treatment of postmenopausal women with early
breast cancer: first results of the ATAC randomised trial. Lancet.
359:2131–2139. 2002. View Article : Google Scholar
|
|
43.
|
Baum M, Buzdar A, Cuzick J, et al:
Anastrozole alone or in combination with tamoxifen versus tamoxifen
alone for adjuvant treatment of postmenopausal women with
early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen
Alone or in Combination) trial efficacy and safety update analyses.
Cancer. 98:1802–1810. 2003.
|
|
44.
|
Goss PE, Ingle JN, Martino S, et al: A
randomized trial of letrozole in postmenopausal women after five
years of tamoxifen therapy for early-stage breast cancer. N Engl J
Med. 349:1793–1802. 2003.PubMed/NCBI
|
|
45.
|
Curtis RE, Freedman DM, Sherman ME and
Fraumeni JF Jr: Risk of malignant mixed mullerian tumors after
tamoxifen therapy for breast cancer. J Natl Cancer Inst. 96:70–74.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
46.
|
Early Breast Cancer Trialists’
Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal
therapy for early breast cancer on recurrence and 15-year survival:
an overview of the randomised trials. Lancet. 365:1687–1717.
2005.PubMed/NCBI
|
|
47.
|
Bergman L, Beelen ML, Gallee MP, Hollema
H, Benraadt J and van Leeuwen FE: Risk and prognosis of endometrial
cancer after tamoxifen for breast cancer. Comprehensive Cancer
Centres’ ALERT Group. Assessment of Liver and Endometrial cancer
Risk following Tamoxifen. Lancet. 356:881–887. 2000.PubMed/NCBI
|
|
48.
|
Kamigaki Y and Kawakami K: Risk of second
cancer after initial treatment of breast cancer: An Osaka Cancer
Registry Database study. Oncol Lett. 2:963–973. 2011.PubMed/NCBI
|
|
49.
|
Yadav BS, Sharma SC, Patel FD, Ghoshal S,
Kapoor R and Kumar R: Nonbreast second malignancies after treatment
of primary breast cancer. Int J Radiat Oncol Biol Phys.
73:1489–1492. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
50.
|
Matesich SM and Shapiro CL: Second cancers
after breast cancer treatment. Semin Oncol. 30:740–748. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
51.
|
Holli k, Valavaara R, Blanco G, et al:
Finnish Breast Cancer Group: Safety and efficacy results of a
randomized trial comparing adjuvant toremifene and tamoxifen in
postmenopausal patients with node-positive breast cancer. J Clin
Oncol. 18:3487–3494. 2000.
|
|
52.
|
Vogel VG, Costantino JP, Wickerham DL, et
al: National Surgical Adjuvant Breast and Bowel Project (NSABP):
Effects of tamoxifen vs. raloxifene on the risk of developing
invasive breast cancer and other disease outcomes: the NSABP Study
of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 295:2727–2741.
2006. View Article : Google Scholar
|
|
53.
|
Pukkala E, Kyyronen P, Sankila R and Holli
K: Tamoxifen and toremifene treatment of breast cancer and risk of
subsequent endometrial cancer: a population-based case-control
study. Int J Cancer. 100:337–341. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
54.
|
International Breast Cancer Study Group;
Pagani O, Gelber S, Price K, Zahrieh D, Gelber R, et al: Toremifene
and tamoxifen are equally effective for early-stage breast cancer:
first results of International Breast Cancer Study Group Trials
12–93 and 14–93. Ann Oncol. 15:1749–1759. 2004.PubMed/NCBI
|
|
55.
|
Jones ME, van Leeuwen FE, Hoogendoorn WE,
et al: Endometrial cancer survival after breast cancer in relation
to tamoxifen treatment: pooled results from three countries. Breast
Cancer Res. 14:R912012. View Article : Google Scholar : PubMed/NCBI
|
|
56.
|
Le Donne M, Alibrandi A, Ciancimino L,
Azzerboni A, Chiofalo B and Triolo O: Endometrial pathology in
breast cancer patients: Effect of different treatments on
ultrasonographic, hysteroscopic and histological findings. Oncol
Lett. 5:1305–1310. 2013.PubMed/NCBI
|
|
57.
|
Slomovitz BM, Sun CC, Ramirez PT, Bodurka
DC, Diaz P and Lu KH: Does tamoxifen use affect prognosis in breast
cancer patients who develop endometrial cancer? Obstet Gynecol.
104:255–260. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
58.
|
Fles R, Hoogendoorn WE, Platteel I, et al:
Genomic profile of endometrial tumors depends on morphological
subtype, not on tamoxifen exposure. Genes Chromosomes Cancer.
49:699–710. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
59.
|
Huber C, Bouchardy C, Schaffar R, et al:
Antiestrogen therapy for breast cancer modifies the risk of
subsequent cutaneous melanoma. Cancer Prev Res (Phila). 5:82–88.
2012. View Article : Google Scholar : PubMed/NCBI
|
